$DRIO DarioHealth Reports Results for Third Quarte
Post# of 102251
(Total Views: 601)
Posted On: 10/28/2019 8:50:56 AM
$DRIO DarioHealth Reports Results for Third Quarter 2019
NEW YORK and CAESAREA, Israel, Oct. 28, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported financial and operational results for the third quarter ended September 30, 2019.
Q3 2019 Revenues of $1.87 million, a 13% sequential increase over Q2 2019, and a 0.6% decrease compared to Q3 2018
Q3 2019 Gross Profit of $873,000, representing 46.7% of revenues, a sequential increase of 168% over Q2 2019, and an 86% increase over Q3 2018
Operating Loss in Q3 2019 decreased by $1.25 million to $2.8 million, a sequential decline of 48% compared to Q2 2019 and a 31% decrease compared to Q3 2018
Dario demonstrated strategic interest in its platform with potential revenue generating possibly beginning in the first half of 2020, Dance Biopharma partnership and exciting pipeline of potential additional opportunities
Results reflect and support Dario's strategic push into business-to-business (B2B), as sequential revenue growth and client wins were generated in combination with a lower expense structure
CEO, Erez Raphael, stated, "In the third quarter, we believe that we produced tangible evidence that broadening our focus from the direct-to-consumer (D2C) channel alone to include the B2B channel is working well. We grew Dario's top-line while significantly improving gross margins and reducing losses. This quarter's performance also highlights the potential of our high margin SaaS oriented membership program. As previously mentioned, the resulting benefits of this B2B channel focus are measurable in terms of larger patient adoption, more certain revenue streams and lower customer acquisition costs.
In July 2019, Dario successfully launched a U.S. Food and Drug Administration cleared hypertension extension of its chronic disease management platform. We're excited about the versatility of our platform and that we can now potentially help 75 million patients in the U.S. who suffer from this condition. We've received initial positive feedback from existing users about their ability to manage both diabetes and hypertension on our digital platform and we are excited to offer our technology to address an additional potential large market opportunity.
In September 2019, Dario announced its first strategic partnership with a private company, Dance Biopharm Holdings, Inc. Dario's platform will be integrated with Dance's smart inhaler to provide patients with automated, real-time treatment data through our advanced mobile application. This partnership may generate revenues in 2020 and beyond. We believe this partnership will be the first of many as we seek to combine our technology with other therapeutic, device and service offerings. We believe this highlights the compatibility and versatility of Dario's digital chronic condition management platform to integrate with other devices to assist in managing other diseases.
Finally, we continued to win new clients and increase the pipeline of payers, employers, and providers who want an integrated solution that provides value and accountability driven healthcare, enabled by Dario's user-centric and evidence-based platform.
Management's continued acceptance of a portion of its compensation in shares is another ongoing contributor to a reduced cash burn and a reflection of our management's belief in Dario's future.
As we assess the global healthcare market and Dario's place in it, we are confident that we have built a platform technology which will deliver better care at a lower cost for patients with chronic diseases.
Financial Results for the Three Months Ended September 30, 2019:
Revenue for the third quarter ended September 30, 2019 was $1.87 million, a 13% sequential increase over Q2 2019 and a 0.6% decrease from $1.88 million in the third quarter ended September 30, 2018.
Gross profit of $873,000, representing 46.7% of revenues, was recorded for the three months ended September 30, 2019, an increase of 86%, or $405,000, compared to gross profit of $468,000 for the three months ended September 30, 2018.
Operating loss for the three months ended September 30, 2019 decreased by $1.25 million to $2.8 million, as compared to a $4.5 million operating loss for the three months ended September 30, 2018.
Net loss attributable to holders of common stock decreased by $1.26 million to $2.8 million for the three months ended September 30, 2019, as compared to $4.1 million for the three months ended September 30, 2018.
Our new B2B focus has allowed us to be more efficient with our use of cash, extending our runway of existing balance sheet resources.
As of September 30, 2019, cash and cash equivalents totaled approximately $4.6 million.
Non-GAAP billings for the three months ended September 30, 2019 were $1.78 million, a 20% decrease from $2.2 million in the three months ended September 30, 2019. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Financial Results for the Nine Months Ended September 30, 2019:
Revenue for the nine months ended September 30, 2019 was $5.76 million, a 1.2% increase from $5.69 million for the nine months ended September 30, 2018.
Gross profit of $1.76 million was recorded for the nine months ended September 30, 2019, an increase of 14%, or $215,000, compared to gross profit of $1.54 million for the nine months ended September 30, 2018.
Operating loss for the nine months ended September 30, 2019 increased by $762,000 to $13.5 million, compared to a $12.8 million operating loss for the nine months ended September 30, 2018.
Net loss attributable to holders of common stock increased by $743,000 to $13.56 million for the nine months ended September 30, 2019, as compared to $12.82 million for the nine months ended September 30, 2018.
Non-GAAP billings for the nine months ended September 30, 2019 were $6.34 million, a 4.2% increase from $6.08 million in the nine months ended September 30, 2019. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
A Company investor presentation is available at: http://mydario.investorroom.com/
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, please go to: http://dariohealth.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company"
related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company describes its belief that the third quarter produced tangible evidence that broadening its focus from the D2C channel to the B2B channel is working well, that the Company is excited to offer its hypertension extension product to address a potential large market opportunity, that its partnership with Dance Biopharma may generate revenues in the first half of 2020 and beyond, its belief that such partnership will be the first of many to combine the Company's technology with other therapeutic, device and service offerings and that such partnership highlights the compatibility and versatility of Dario's platform with other devices to assist in managing other diseases and the belief that management is confident that it has built a platform technology which will deliver better care at a lower cost for patients with chronic diseases. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Non-GAAP Financial Measures
We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Billings (non-GAAP). We define billings as revenue recognized in accordance with GAAP plus the change in deferred revenue from the beginning to the end of the period and adjustment to the deferred revenue balance due to adoption of the new revenue recognition standard less any deferred revenue balances acquired from business combination(s) during the period. We consider billings to be a useful metric for management and investors because billings drive future revenue, which is an important indicator of the health and viability of our business. There are a number of limitations related to the use of billings instead of GAAP revenue. First, billings include amounts that have not yet been recognized as revenue and are impacted by the term of security and support agreements. Second, we may calculate billings in a manner that is different from peer companies that report similar financial measures. Management accounts for these limitations by providing specific information regarding GAAP revenue and evaluating billings together with GAAP revenue.
DARIOHEALTH CORP. CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands
September30,
December31,
2019
2018
Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$
4,585
$
10,997
Restricted bank deposits
189
180
Trade Receivables
519
168
Inventories
1,473
1,377
Other accounts receivable and prepaid expenses
392
591
Total current assets
7,158
13,313
LEASE DEPOSITS
52
43
OPERATING LEASE RIGHT OF USE ASSET
719
-
PROPERTY AND EQUIPMENT, NET
674
733
Total assets
$
8,603
$
14,089
DARIOHEALTH CORP. CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (except stock and stock data)
September 30,
December 31,
2019
2018
Unaudited
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables
$
1,406
$
2,574
Deferred revenues
1,311
736
Operating lease liability
287
-
Other accounts payable and accrued expenses
1,215
1,854
Total current liabilities
4,219
5,164
OPERATING LEASE LIABILITY
477
-
STOCKHOLDERS' EQUITY
Common Stock of $0.0001 par value – Authorized: 160,000,000 shares at September 30, 2019 (unaudited) and December 31, 2018; Issued and Outstanding: 43,683,840 and 36,607,755 shares at September 30, 2019 (unaudited) and December 31, 2018, respectively
8
8
Preferred Stock of $0.0001 par value - Authorized: 5,000,000 shares at September 30, 2019 (unaudited) and December 31, 2018; Issued and Outstanding: None at September 30, 2019 (unaudited) and December 31, 2018
-
-
Additional paid-in capital
106,716
98,171
Accumulated deficit
(102,817)
(89,254)
Total stockholders' equity
3,907
8,925
Total liabilities and stockholders' equity
$
8,603
$
14,089
DARIOHEALTH CORP. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS U.S. dollars in thousands (except stock and stock data)
Three months endedSeptember 30
Nine months endedSeptember 30
2019
2018
2019
2018
Unaudited
Unaudited
Revenues
$
1,868
$
1,879
$
5,761
$
5,694
Cost of revenues
995
1,411
4,004
4,152
Gross profit
873
468
1,757
1,542
Operating expenses:
Research and development
$
859
$
997
$
2,852
$
2,749
Sales and marketing
1,865
2,816
8,804
7,049
General and administrative
948
709
3,625
4,506
Total operating expenses
3,672
4,522
15,281
14,304
Operating loss
(2,799)
(4,054)
(13,524)
(12,762)
Financial expenses, net:
Revaluation of warrants
-
*)-
-
1
Other financial expense, net
(6)
(9)
(39)
(59)
Total financial expenses, net
(6)
(9)
(39)
(58)
Net loss
$
(2,805)
$
(4,063)
$
(13,563)
$
(12,820)
Deemed dividend related to warrant exchange
$
-
$
-
$
-
$
493
Net loss attributable to holders of Common Stock
$
(2,805)
$
(4,063)
$
(13,563)
$
(13,313)
Net loss per share
Basic and diluted loss per share
$
(0.06)
$
(0.17)
$
(0.28)
$
(0.67)
Weighted average number of Common Stock used in computing basic and diluted net loss per share
50,730,253
23,533,328
49,101,850
19,733,291
DARIOHEALTH CORP. CONSOLIDATED STATEMENTS OF CASH FLOWS U.S. dollars in thousands
Nine months endedSeptember 30,
2019
2018
Unaudited
Cash flows from operating activities:
Net loss
$
(13,563)
$
(12,820)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation and Common Stock to service providers
1,928
3,284
Depreciation
138
160
Amortization of operating lease right of use
160
-
Increase is trade receivables
(351)
(92)
Decrease in accounts receivables and prepaid expenses
199
81
Decrease (increase) in inventories
(96)
164
Increase (decrease) in trade payables
(1,168)
351
Increase (decrease) in other accounts payable and accrued expenses
(580)
457
Increase in deferred revenues
575
385
Change in operating lease liability
(115)
-
Change in fair value of warrants to purchase shares of Common Stock
-
(1)
Net cash used in operating activities
(12,873)
(8,031)
Cash flows from investing activities:
Maturities (investment) of restricted bank deposit
(9)
74
Investment in lease deposits
(9)
(5)
Purchase of property and equipment
(79)
(49)
Net cash provided by (used in) investing activities
(97)
20
Cash flows from financing activities:
Proceeds from issuance of Common Stock, Preferred Stock and warrants, net of issuance cost
6,558
15,720
Net cash provided by financing activities
6,558
15,720
Increase (decrease) in cash and cash equivalents
(6,412)
7,709
Cash and cash equivalents at the beginning of the period
10,997
3,718
Cash and cash equivalents at the end of the period
$
4,585
$
11,427
Non-cash investing and financing activities:
Payment for directors and consultants under Shares for Salary Program
$
59
$
286
DARIOHEALTH CORP. Reconciliation of Revenue to Billings (Non-GAAP) U.S. dollars in thousands
Three Months Ended
September 30,
Nine Months Ended
September 30,
2019
2018
2019
2018
GAAP Revenues
$1,868
$1,879
$5,761
$5,694
Add:
Change in Deferred Revenues
($87)
$335
$575
$385
Billings (Non-GAAP)
$1,781
$2,214
$6,336
$6,079
Contacts:
DarioHealth Corporate Contact: Claudia Levi, Content & Communications Manager, claudia@mydario.com, +1-347-767-4220
https://c212.net/c/img/favicon.png?sn=LN16772...2019-10-28 View original content:http://www.prnewswire.com/news-releases/dariohealth-reports-results-for-third-quarter-2019-300946140.html
SOURCE DarioHealth Corp.
NEW YORK and CAESAREA, Israel, Oct. 28, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported financial and operational results for the third quarter ended September 30, 2019.
Q3 2019 Revenues of $1.87 million, a 13% sequential increase over Q2 2019, and a 0.6% decrease compared to Q3 2018
Q3 2019 Gross Profit of $873,000, representing 46.7% of revenues, a sequential increase of 168% over Q2 2019, and an 86% increase over Q3 2018
Operating Loss in Q3 2019 decreased by $1.25 million to $2.8 million, a sequential decline of 48% compared to Q2 2019 and a 31% decrease compared to Q3 2018
Dario demonstrated strategic interest in its platform with potential revenue generating possibly beginning in the first half of 2020, Dance Biopharma partnership and exciting pipeline of potential additional opportunities
Results reflect and support Dario's strategic push into business-to-business (B2B), as sequential revenue growth and client wins were generated in combination with a lower expense structure
CEO, Erez Raphael, stated, "In the third quarter, we believe that we produced tangible evidence that broadening our focus from the direct-to-consumer (D2C) channel alone to include the B2B channel is working well. We grew Dario's top-line while significantly improving gross margins and reducing losses. This quarter's performance also highlights the potential of our high margin SaaS oriented membership program. As previously mentioned, the resulting benefits of this B2B channel focus are measurable in terms of larger patient adoption, more certain revenue streams and lower customer acquisition costs.
In July 2019, Dario successfully launched a U.S. Food and Drug Administration cleared hypertension extension of its chronic disease management platform. We're excited about the versatility of our platform and that we can now potentially help 75 million patients in the U.S. who suffer from this condition. We've received initial positive feedback from existing users about their ability to manage both diabetes and hypertension on our digital platform and we are excited to offer our technology to address an additional potential large market opportunity.
In September 2019, Dario announced its first strategic partnership with a private company, Dance Biopharm Holdings, Inc. Dario's platform will be integrated with Dance's smart inhaler to provide patients with automated, real-time treatment data through our advanced mobile application. This partnership may generate revenues in 2020 and beyond. We believe this partnership will be the first of many as we seek to combine our technology with other therapeutic, device and service offerings. We believe this highlights the compatibility and versatility of Dario's digital chronic condition management platform to integrate with other devices to assist in managing other diseases.
Finally, we continued to win new clients and increase the pipeline of payers, employers, and providers who want an integrated solution that provides value and accountability driven healthcare, enabled by Dario's user-centric and evidence-based platform.
Management's continued acceptance of a portion of its compensation in shares is another ongoing contributor to a reduced cash burn and a reflection of our management's belief in Dario's future.
As we assess the global healthcare market and Dario's place in it, we are confident that we have built a platform technology which will deliver better care at a lower cost for patients with chronic diseases.
Financial Results for the Three Months Ended September 30, 2019:
Revenue for the third quarter ended September 30, 2019 was $1.87 million, a 13% sequential increase over Q2 2019 and a 0.6% decrease from $1.88 million in the third quarter ended September 30, 2018.
Gross profit of $873,000, representing 46.7% of revenues, was recorded for the three months ended September 30, 2019, an increase of 86%, or $405,000, compared to gross profit of $468,000 for the three months ended September 30, 2018.
Operating loss for the three months ended September 30, 2019 decreased by $1.25 million to $2.8 million, as compared to a $4.5 million operating loss for the three months ended September 30, 2018.
Net loss attributable to holders of common stock decreased by $1.26 million to $2.8 million for the three months ended September 30, 2019, as compared to $4.1 million for the three months ended September 30, 2018.
Our new B2B focus has allowed us to be more efficient with our use of cash, extending our runway of existing balance sheet resources.
As of September 30, 2019, cash and cash equivalents totaled approximately $4.6 million.
Non-GAAP billings for the three months ended September 30, 2019 were $1.78 million, a 20% decrease from $2.2 million in the three months ended September 30, 2019. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Financial Results for the Nine Months Ended September 30, 2019:
Revenue for the nine months ended September 30, 2019 was $5.76 million, a 1.2% increase from $5.69 million for the nine months ended September 30, 2018.
Gross profit of $1.76 million was recorded for the nine months ended September 30, 2019, an increase of 14%, or $215,000, compared to gross profit of $1.54 million for the nine months ended September 30, 2018.
Operating loss for the nine months ended September 30, 2019 increased by $762,000 to $13.5 million, compared to a $12.8 million operating loss for the nine months ended September 30, 2018.
Net loss attributable to holders of common stock increased by $743,000 to $13.56 million for the nine months ended September 30, 2019, as compared to $12.82 million for the nine months ended September 30, 2018.
Non-GAAP billings for the nine months ended September 30, 2019 were $6.34 million, a 4.2% increase from $6.08 million in the nine months ended September 30, 2019. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
A Company investor presentation is available at: http://mydario.investorroom.com/
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, please go to: http://dariohealth.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company"
related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company describes its belief that the third quarter produced tangible evidence that broadening its focus from the D2C channel to the B2B channel is working well, that the Company is excited to offer its hypertension extension product to address a potential large market opportunity, that its partnership with Dance Biopharma may generate revenues in the first half of 2020 and beyond, its belief that such partnership will be the first of many to combine the Company's technology with other therapeutic, device and service offerings and that such partnership highlights the compatibility and versatility of Dario's platform with other devices to assist in managing other diseases and the belief that management is confident that it has built a platform technology which will deliver better care at a lower cost for patients with chronic diseases. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Non-GAAP Financial Measures
We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Billings (non-GAAP). We define billings as revenue recognized in accordance with GAAP plus the change in deferred revenue from the beginning to the end of the period and adjustment to the deferred revenue balance due to adoption of the new revenue recognition standard less any deferred revenue balances acquired from business combination(s) during the period. We consider billings to be a useful metric for management and investors because billings drive future revenue, which is an important indicator of the health and viability of our business. There are a number of limitations related to the use of billings instead of GAAP revenue. First, billings include amounts that have not yet been recognized as revenue and are impacted by the term of security and support agreements. Second, we may calculate billings in a manner that is different from peer companies that report similar financial measures. Management accounts for these limitations by providing specific information regarding GAAP revenue and evaluating billings together with GAAP revenue.
DARIOHEALTH CORP. CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands
September30,
December31,
2019
2018
Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$
4,585
$
10,997
Restricted bank deposits
189
180
Trade Receivables
519
168
Inventories
1,473
1,377
Other accounts receivable and prepaid expenses
392
591
Total current assets
7,158
13,313
LEASE DEPOSITS
52
43
OPERATING LEASE RIGHT OF USE ASSET
719
-
PROPERTY AND EQUIPMENT, NET
674
733
Total assets
$
8,603
$
14,089
DARIOHEALTH CORP. CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (except stock and stock data)
September 30,
December 31,
2019
2018
Unaudited
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables
$
1,406
$
2,574
Deferred revenues
1,311
736
Operating lease liability
287
-
Other accounts payable and accrued expenses
1,215
1,854
Total current liabilities
4,219
5,164
OPERATING LEASE LIABILITY
477
-
STOCKHOLDERS' EQUITY
Common Stock of $0.0001 par value – Authorized: 160,000,000 shares at September 30, 2019 (unaudited) and December 31, 2018; Issued and Outstanding: 43,683,840 and 36,607,755 shares at September 30, 2019 (unaudited) and December 31, 2018, respectively
8
8
Preferred Stock of $0.0001 par value - Authorized: 5,000,000 shares at September 30, 2019 (unaudited) and December 31, 2018; Issued and Outstanding: None at September 30, 2019 (unaudited) and December 31, 2018
-
-
Additional paid-in capital
106,716
98,171
Accumulated deficit
(102,817)
(89,254)
Total stockholders' equity
3,907
8,925
Total liabilities and stockholders' equity
$
8,603
$
14,089
DARIOHEALTH CORP. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS U.S. dollars in thousands (except stock and stock data)
Three months endedSeptember 30
Nine months endedSeptember 30
2019
2018
2019
2018
Unaudited
Unaudited
Revenues
$
1,868
$
1,879
$
5,761
$
5,694
Cost of revenues
995
1,411
4,004
4,152
Gross profit
873
468
1,757
1,542
Operating expenses:
Research and development
$
859
$
997
$
2,852
$
2,749
Sales and marketing
1,865
2,816
8,804
7,049
General and administrative
948
709
3,625
4,506
Total operating expenses
3,672
4,522
15,281
14,304
Operating loss
(2,799)
(4,054)
(13,524)
(12,762)
Financial expenses, net:
Revaluation of warrants
-
*)-
-
1
Other financial expense, net
(6)
(9)
(39)
(59)
Total financial expenses, net
(6)
(9)
(39)
(58)
Net loss
$
(2,805)
$
(4,063)
$
(13,563)
$
(12,820)
Deemed dividend related to warrant exchange
$
-
$
-
$
-
$
493
Net loss attributable to holders of Common Stock
$
(2,805)
$
(4,063)
$
(13,563)
$
(13,313)
Net loss per share
Basic and diluted loss per share
$
(0.06)
$
(0.17)
$
(0.28)
$
(0.67)
Weighted average number of Common Stock used in computing basic and diluted net loss per share
50,730,253
23,533,328
49,101,850
19,733,291
DARIOHEALTH CORP. CONSOLIDATED STATEMENTS OF CASH FLOWS U.S. dollars in thousands
Nine months endedSeptember 30,
2019
2018
Unaudited
Cash flows from operating activities:
Net loss
$
(13,563)
$
(12,820)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation and Common Stock to service providers
1,928
3,284
Depreciation
138
160
Amortization of operating lease right of use
160
-
Increase is trade receivables
(351)
(92)
Decrease in accounts receivables and prepaid expenses
199
81
Decrease (increase) in inventories
(96)
164
Increase (decrease) in trade payables
(1,168)
351
Increase (decrease) in other accounts payable and accrued expenses
(580)
457
Increase in deferred revenues
575
385
Change in operating lease liability
(115)
-
Change in fair value of warrants to purchase shares of Common Stock
-
(1)
Net cash used in operating activities
(12,873)
(8,031)
Cash flows from investing activities:
Maturities (investment) of restricted bank deposit
(9)
74
Investment in lease deposits
(9)
(5)
Purchase of property and equipment
(79)
(49)
Net cash provided by (used in) investing activities
(97)
20
Cash flows from financing activities:
Proceeds from issuance of Common Stock, Preferred Stock and warrants, net of issuance cost
6,558
15,720
Net cash provided by financing activities
6,558
15,720
Increase (decrease) in cash and cash equivalents
(6,412)
7,709
Cash and cash equivalents at the beginning of the period
10,997
3,718
Cash and cash equivalents at the end of the period
$
4,585
$
11,427
Non-cash investing and financing activities:
Payment for directors and consultants under Shares for Salary Program
$
59
$
286
DARIOHEALTH CORP. Reconciliation of Revenue to Billings (Non-GAAP) U.S. dollars in thousands
Three Months Ended
September 30,
Nine Months Ended
September 30,
2019
2018
2019
2018
GAAP Revenues
$1,868
$1,879
$5,761
$5,694
Add:
Change in Deferred Revenues
($87)
$335
$575
$385
Billings (Non-GAAP)
$1,781
$2,214
$6,336
$6,079
Contacts:
DarioHealth Corporate Contact: Claudia Levi, Content & Communications Manager, claudia@mydario.com, +1-347-767-4220
https://c212.net/c/img/favicon.png?sn=LN16772...2019-10-28 View original content:http://www.prnewswire.com/news-releases/dariohealth-reports-results-for-third-quarter-2019-300946140.html
SOURCE DarioHealth Corp.
(0)
(0)Scroll down for more posts ▼